Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Yang, Mingli ^a   Jiang, Guohua ^a   Li, Wenjing ^a   Qiu, Kai ^a   Zhang, Min ^a   Carter, Christopher M ^a   Al Quran, Samer Z ^a   Li, Ying ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Acute myeloid leukemia; Aptamer; Biomarker; Cell SELEX; Siglec 5

Indexed keywords

APTAMER; CELL SURFACE PROTEIN; PROTEINASE; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SINGLE STRANDED DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW CELL; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL SURFACE; CONTROLLED STUDY; DNA LIBRARY; DRUG BINDING SITE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKOCYTE; MOLECULAR RECOGNITION; MONOCYTE; PHENOTYPE; RECOGNITION; TARGET CELL;

ACUTE DISEASE; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; DIAGNOSIS, DIFFERENTIAL; DNA, SINGLE-STRANDED; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LECTINS; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTES; MEMBRANE PROTEINS; POLYMERASE CHAIN REACTION; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; SELEX APTAMER TECHNIQUE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84892187344     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-5     Document Type: Article

References (38)

1. Age and acute myeloid leukemia. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH, Blood 2006 107 3481 3485 10.1182/blood-2005-09-3724 16455952
2. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, et al. Blood 2010 115 453 474 10.1182/blood-2009-07-235358 19880497
3. Acute myeloid leukemia. O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, et al. J Natl Compr Canc Netw 2012 10 984 1021 22878824
4. Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives. Sekeres MA, Haematologica 2008 93 1769 1772 10.3324/haematol.2008.000497 19050066
5. The challenge of risk stratification in acute myeloid leukemia with normal karyotype. Zaidi SZ, Owaidah T, Al SF, Ahmed SY, Chaudhri N, Aljurf M, Hematol Oncol Stem Cell Ther 2008 1 141 158 20063545
6. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W, J Hematol Oncol 2009 2 23 10.1186/1756-8722-2-23 19490647
7. Aptamers and the RNA world, past and present. Gold L, Janjic N, Jarvis T, Schneider D, Walker JJ, Wilcox SK, Zichi D, Cold Spring Harb Perspect Biol 2012 4 1 9
8. Aptamer applications for targeted cancer therapy. Barbas AS, Mi J, Clary BM, White RR, Future Oncol 2010 6 1117 1126 10.2217/fon.10.67 20624124
9. Cell-specific aptamers for targeted therapies. Cerchia L, Giangrande PH, McNamara JO, de F,V, Methods Mol Biol 2009 535 59 78 10.1007/978-1-59745-557-2-5 19377980
10. Aptamers as potential nucleic acid pharmaceuticals. Ellington AD, Conrad R, Biotechnol Annu Rev 1995 1 185 214 9704089
11. The use of aptamers in large arrays for molecular diagnostics. Brody EN, Willis MC, Smith JD, Jayasena S, Zichi D, Gold L, Mol Diagn 1999 4 381 388 10.1016/S1084-8592(99)80014-9 10671648
12. Development of aptamer therapeutics. Bunka DH, Platonova O, Stockley PG, Curr Opin Pharmacol 2010 10 557 562 10.1016/j.coph.2010.06.009 20638902
13. Aptamers evolved from live cells as effective molecular probes for cancer study. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, et al. Proc Natl Acad Sci USA 2006 103 11838 11843 10.1073/pnas. 0602615103 16873550
14. Nucleic acid aptamers targeting cell-surface proteins. Dua P, Kim S, Lee DK, Methods 2011 54 215 225 10.1016/j.ymeth.2011.02.002 21300154
15. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. Blank M, Weinschenk T, Priemer M, Schluesener H, J Biol Chem 2001 276 16464 16468 10.1074/jbc.M100347200 11279054
16. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L, Proc Natl Acad Sci USA 2003 100 15416 15421 10.1073/pnas.2136683100 14676325
17. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W, Mol Cell Proteomics 2007 6 2230 2238 10.1074/mcp.M700026-MCP200 17875608
18. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W, J Proteome Res 2008 7 2133 2139 10.1021/pr700894d 18363322
19. Molecular recognition of acute myeloid leukemia using aptamers. Sefah K, Tang ZW, Shangguan DH, Chen H, Lopez-Colon D, Li Y, Parekh P, Martin J, et al. Leukemia 2009 23 235 244 10.1038/leu.2008.335 19151784
20. PTK7: A new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemia. Jiang G, Zhang M, Yue B, Yang M, Carter C, Al-Quran SZ, Li B, Li Y, Leuk Res 2012 36 1347 1353 10.1016/j.leukres.2012.07.004 22898210
21. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Borowitz MJ, Guenther KL, Shults KE, Stelzer GT, Am J Clin Pathol 1993 100 534 540 8249893
22. Ten-color immunophenotyping of hematopoietic cells. Wood BL, Curr Protoc Cytom 2005 Chapter 6 6.21.1 6.21.11
23. Sample preparation by in-gel digestion for mass spectrometry-based proteomics. Granvogl B, Ploscher M, Eichacker LA, Anal Bioanal Chem 2007 389 991 1002 10.1007/s00216-007-1451-4 17639354
24. Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33. Cornish AL, Freeman S, Forbes G, Ni J, Zhang M, Cepeda M, Gentz R, Augustus M, et al. Blood 1998 92 2123 2132 9731071
25. CD33-related siglecs as potential modulators of inflammatory responses. Crocker PR, McMillan SJ, Richards HE, Ann N Y Acad Sci 2012 1253 102 111 10.1111/j.1749-6632.2011.06449.x 22352893
26. Identification of the CD33-related Siglec receptor, Siglec-5 (CD170), as a useful marker in both normal myelopoiesis and acute myeloid leukaemias. Virgo P, Denning-Kendall PA, Erickson-Miller CL, Singha S, Evely R, Hows JM, Freeman SD, Br J Haematol 2003 123 420 430 10.1046/j.1365-2141.2003.04625.x 14617000
27. The role of flow cytometry in myelodysplastic syndromes. Loken MR, Wells DA, J Natl Compr Canc Netw 2008 6 935 941 18926102
28. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, Venzon D, Rick ME, Blood 2001 98 979 987 10.1182/blood.V98.4.979 11493442
29. Flow cytometric diagnosis of myelodysplasia and myeloproliferative disorders. Wood BL, J Biol Regul Homeost Agents 2004 18 141 145 15471218
30. Mass spectrometry accelerates membrane protein analysis. Savas JN, Stein BD, Wu CC, Yates JR III, Trends Biochem Sci 2011 36 388 396 21616670
31. Derangement of transcription factor profiles during in vitro differentiation of HL60 and NB4 cells. Pass MB, Borregaard N, Cowland JB, Leuk Res 2007 31 827 837 10.1016/j.leukres.2006.07.019 16942795
32. [Effect of translocation t(15;17) on the gene expression regulation of myeloblastin during all trans retinoic acid induced myeloid differentiation in human leukemic cells]. Ballerini P, Besancon F, Cayre YE, C R Seances Soc Biol Fil 1995 189 521 530 8564566
33. Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. Leupin N, Kuhn A, Hugli B, Grob TJ, Jaggi R, Tobler A, Delorenzi M, Fey MF, Br J Haematol 2006 135 520 523 10.1111/j.1365-2141.2006.06342.x 17061979
34. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Walter RB, Appelbaum FR, Estey EH, Bernstein ID, Blood 2012 119 6198 6208 10.1182/blood-2011-11-325050 22286199
35. Siglecs as targets for therapy in immune-cell-mediated disease. O'Reilly MK, Paulson JC, Trends Pharmacol Sci 2009 30 240 248 10.1016/j.tips.2009.02.005 19359050
36. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Nguyen DH, Ball ED, Varki A, Exp Hematol 2006 34 728 735 10.1016/j.exphem.2006.03.003 16728277
37. Aptamer:toxin conjugates that specifically target prostate tumor cells. Chu TC, Marks JW III, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M, Cancer Res 2006 66 5989 5992 10.1158/0008-5472.CAN-05-4583 16778167
38. Tumor-targeted drug delivery with aptamers. Zhang Y, Hong H, Cai W, Curr Med Chem 2011 18 4185 4194 10.2174/092986711797189547 21838687